Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Winder, T; Zhang, W; Yang, D; Ning, Y; Bohanes, P; Gerger, A; Wilson, P; Pohl, A; Mauro, DJ; Langer, C; Rowinsky, EK; Lenz, HJ.
Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients.
Clin Cancer Res. 2010; 16(22):5591-5602
Doi: 10.1158/1078-0432.CCR-10-2092
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Gerger Armin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Purpose: The insulin-like growth factor 1 (IGF1) signaling pathway is an important growth-regulatory pathway, which plays a crucial role in colorectal cancer (CRC) proliferation, differentiation, migration, angiogenesis, and apoptosis. Previous studies showed that hyperactivation of the IGF1 receptor (IGF1R) may result in resistance to anti-epidermal growth factor receptor-targeted treatment. We tested whether germline variations within the IGF1 pathway are associated with clinical outcome in wild-type (wt) KRAS drug-refractory metastatic CRC (mCRC) patients who were treated with cetuximab monotherapy (IMC-0144). Experimental Design: Formalin-fixed, paraffin-embedded (FFPE) tissue samples of 130 drug-refractory mCRC patients enrolled in IMC-0144, a phase II clinical trial of cetuximab monotherapy, were analyzed. gDNA was extracted from dissected FFPE tumor tissue, and KRAS mutation status and six potentially functional IGF1 and IGF1R polymorphisms were analyzed using direct DNA sequencing or PCR-RFLP. Tumor response analysis was based on recursive partitioning, and survival analyses were based on univariate and multivariate hazard regression models. Results: In univariate and multivariate analyses, five IGF pathway single-nucleotide polymorphisms were significantly associated with progression-free survival (PFS) and/or overall survival (OS). In multivariate combined risk allele analysis, the additive model for PFS and OS was significantly associated with the number of risk alleles in wt KRAS patients (P = 0.001 and P = 0.02, respectively). In addition, wt KRAS patients harboring IGF1 rs2946834 A/A genotype had a 50% objective response rate compared with 0% for A/G genotype. Conclusions: These results indicate that IGF1 pathway polymorphisms are potential predictive/prognostic molecular markers for cetuximab efficacy in wt KRAS mCRC patients. Prospective biomarkerembedded clinical trials are warranted to validate our findings. Clin Cancer Res; 16(22); 5591-602. (C) 2010 AACR.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use
- Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use
- Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology
- Genetic Testing -
- Germ-Line Mutation - genetics
- Humans -
- Insulin-Like Growth Factor I - metabolism
- Middle Aged -
- Multivariate Analysis -
- Polymorphism, Single Nucleotide - genetics
- Proto-Oncogene Proteins - genetics
- Signal Transduction - genetics
- ras Proteins - genetics